UK MHRA Says Genetic Biobank Could Transform Drug Safety Monitoring Through Personalized Medicine
Executive Summary
The biobank, which the UK regulator believes puts it at the forefront of innovation in the field of drug safety monitoring, will enter a pilot in June, starting with the gout treatment allopurinol and related rare, severe skin reactions.
You may also be interested in...
UK LifeSci Funding Boost – Medtech Research And Regulation To Benefit
Rebranded Health Innovation Networks, Biobanks and clinical trials get share of £650m UK funding earmarked to support research, manufacturing, skills development and access to diagnosis and treatment.
EU CHMP Opinions And MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
Additional Analyses Help Idorsia Secure English Funding For Chronic Insomnia Drug Quviviq
Quviviq is to become the first dual orexin receptor antagonist available on the National Health Service. Just over 20,000 people in England could receive treatment with the drug in its first year, says the health technology assessment institute, NICE.